Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Olezarsen · Tryngolza, ISIS-678354

Oligonucleotide (Antisense oligonucleotide) · Gene silencing: apolipoprotein C-III (APOC3) · developed by Ionis Pharms

Approved FDA, Dec 2024

IONS Developer

1 Registered trials

What is Olezarsen?

Olezarsen is an antisense oligonucleotide conjugated to GalNAc that binds apoC-III mRNA, reducing apoC-III protein levels. This increases clearance of triglycerides and VLDL, reducing triglyceride levels in familial chylomicronemia syndrome and severe hypertriglyceridemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Tryngolza, ISIS-678354, AKCEA-APOCIII-LRx
Drug type: Oligonucleotide (Antisense oligonucleotide)
Targets: apolipoprotein C-III (APOC3)
Mechanism: Gene silencing: apolipoprotein C-III (APOC3)
Pathways: triglyceride metabolism, VLDL clearance
Therapy area: Metabolic
Developer: Ionis Pharms Inc (IONS)
FDA status: Approved as Tryngolza (December 19, 2024), NDA218614 · FDA label
UNII: S3RS2SA30L

✅ FDA-approved uses

Familial chylomicronemia syndrome
Severe hypertriglyceridemia

From the indications section of the FDA label (version of Jul 3, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05681351	Phase 3	Severe Hypertriglyceridemia	Active not recruiting	IONS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Severe Hypertriglyceridemia

Other drugs acting on APOC3

Plozasiran FDA approved

More from Ionis Pharms

Donidalorsen FDA approved Zilganersen FDA approved BIIB094 Phase 1 ION224 Phase 2 ION269 Phase 1 ION337 Phase 1/2 ION356 Phase 1 ION363 Phase 3 ION440 Phase 1/2 ION464 Phase 1 ION717 Phase 1/2 ION775 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IONS page.

Follow IONS, the company behind Olezarsen

See IONS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IONS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z